Abstract P2-12-06: Implementing a comprehensive genetic risk assessment and testing service at an outpatient breast imaging center

Breast cancer is the most common cancer in women, and there are a variety of available methods to determine which women have an above-average risk to develop breast cancer. However, it can be a challenge to identify patients who may benefit from genetic counseling and should be offered genetic testing. This study examines our data and experience in performing genetic risk assessment and offering on-site genetic counseling in an outpatient breast imaging center. A screening questionnaire asking about personal and family cancer history was created and given to every patient coming in for either screening or diagnostic mammogram. The questionnaires were reviewed by both the breast radiologist and nurse navigator, and those identified as appropriate were offered appointments with the genetic counselor. Genetic counseling appointments are available two days per month. Data was obtained over an eight month period from August 2012- March 2013. During this time, 8768 mammograms were performed and 406 individuals were identified as having a history suspicious for hereditary breast and ovarian cancer and offered an appointment with a genetic counselor. Out of these 406 individuals, 83 scheduled appointments with the genetic counselor, 108 declined appointments, and 215 are pending. Some of the genetic counseling appointments were made after March 31, 2013 and the outcomes are not included at this time. Thirty-six patients were ultimately seen for genetic counseling and risk assessment in this time frame, with 28 undergoing testing. Out of the 28 patients tested during this time period, one was positive and one had a variant of unknown significance. Out of the 36 patients seen for genetic counseling, 27 were identified as increased risk for breast cancer either by having a Gail risk assessment score ≥1.67% or Tyrer-Cuzick risk assessment score ≥19.5% and were eligible for chemoprevention or breast MRI, respectively. This clinic model demonstrates that on-site genetic counseling is feasible in an outpatient breast imaging setting. Prior to offering on-site genetic counseling, this center used the same questionnaire to identify patients and sent a recommendation for genetic counseling to the referring physician ordering the mammogram. This system relied on the physician to make a referral to an off-site genetic counselor. From the period of May 2012- August 2012, 139 patients were identified by the same questionnaire with 17 patients being referred to genetic counseling, and only 3 of these patients were ultimately seen by the genetic counselor. By providing on-site genetic counseling, the percentage of patients seen for genetic counseling increased from 2.15% (3/139) to 8.87% (36/406). In addition, more outcomes are known since 100% of patients identified to be at risk for Hereditary Breast and Ovarian cancer were offered genetic counseling, and if a patient declined, a reason was documented. The risk assessment algorithm outlined here identified more patients that either tested positive for a BRCA mutation or were at an increased 5-year or lifetime risk to develop breast cancer that may not have been detected otherwise.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-12-06.

Interferon-gamma receptor deficiency mimicking Langerhans' cell histiocytosis

Two patients who were initially given a diagnosis of Langerhans' cell histiocytosis on the basis of the clinical, radiologic, and biopsy findings had mycobacterial infection subsequently identified. The correct diagnosis of dominant partial interferon-gamma receptor deficiency was established.

Social cognitive determinants of drinking in young adults: beyond the alcohol expectancies paradigm

In prior investigations of the psychology of drinking behavior, drinkers' positive expectancies regarding the effects of alcohol have been studied extensively. From a social cognitive point of view, however, several additional psychological factors also deserve attention, namely negative expectancies, social influence, and self-efficacy expectations. In a representative sample of 161 university students, this study examined to what extent inclusion of these additional social cognitive factors enhanced the predictive power of the predominant alcohol-expectancies model of drinking behavior, and to what extent all four social cognitive factors were related to the uptake and cessation of drinking behavior. The three additional social cognitive factors contributed 17% to the explained variance in drinking behavior, in addition to the 18% accounted for by positive expectancies. The constructs with the greatest predictive strength all pertained to the social effects and social context of drinking. The most important predictors of drinking behavior were found to differ for male versus female students, and for students living with their parents versus those living on their own. The data on drinking acquisition and cessation suggest that in this sample little change in drinking behavior could be expected. The social cognitive factors were strongly related to acquisition stages but only weakly to cessation stages. Recommendations for interventions aimed at lowering alcohol intake are given.

Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers

BACKGROUND

Human solid tumors undergo clonal evolution as they progress, but evidence for specific sequences of genetic changes that occur in individual tumors and are recapitulated in other tumors is difficult to obtain.

METHODS

Patterns of amplification of Her-2/neu, c-myc, and cyclin D1 were determined by fluorescence in situ hybridization (FISH) in relation to the presence of p53 dysfunction and ploidy in 60 primary human breast cancers.

RESULTS

We show that there are clusters of genophenotypic abnormalities that distinguish lobular breast cancers from nonlobular tumors; that cyclin D1 amplification occurs prior to the divergence of lobular breast cancers from nonlobular cancers; that p53 dysfunction, Her-2/neu amplification, and c-myc amplification are characteristic features of nonlobular breast cancers, but not of lobular breast cancers; and that the frequencies of amplification of all three oncogenes examined increase progressively with increasing aneuploidy, but that each gene exhibits a different profile of increasing amplification in relation to tumor progression. Early amplification of c-myc appears to be an especially prominent feature of hypertetraploid/hypertetrasomic tumors.

CONCLUSIONS

The data suggest that in tumors containing multiple abnormalities, these abnormalities often accumulate in the same cells within each tumor. Furthermore, the same patterns of accumulation of multiple genophenotypic abnormalities are recapitulated in different tumors.

Re-identification of DNA through an automated linkage process

This work demonstrates how seemingly anonymous DNA database entries can be related to publicly available health information to uniquely and specifically identify the persons who are the subjects of the information even though the DNA information contains no accompanying explicit identifiers such as name, address, or Social Security number and contains no additional fields of personal information. The software program, REID (Re-Identification of DNA), iteratively uncovers unique occurrences in visit-disease patterns across data collections that reveal inferences about the identities of the patients who are the subject of the DNA. Using real-world data, REID established identifiable linkages in 33-100% of the 10,886 cases explicitly surveyed over 8 gene-based diseases.

Determining the identifiability of DNA database entries

CleanGene is a software program that helps determine the identifiability of sequenced DNA, independent of any explicit demographics or identifiers maintained with the DNA. The program computes the likelihood that the release of DNA database entries could be related to specific individuals that are the subjects of the data. The engine within CleanGene relies on publicly available health care data and on knowledge of particular diseases to help relate identified individuals to DNA entries. Over 20 diseases, ranging over ataxias, blood diseases, and sex-linked mutations are accounted for, with 98-100% of individuals found identifiable. We assume the genetic material is released in a linear sequencing format from an individual's genome. CleanGene and its related experiments are useful tools for any institution seeking to provide anonymous genetic material for research purposes.

Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas

Human solid tumors develop multiple genetic abnormalities that accumulate progressively in individual cells during the course of tumor evolution. We sought to determine whether there are specific sequences of occurrence of these progressive evolutionary changes in human breast cancers by performing correlated cell-by-cell measurements of cell DNA content, p53 protein, Her-2/neu protein, and ras protein by multiparameter flow cytometry in 56 primary tumor samples obtained at surgery. In addition, p53 allelic loss and Her-2/neu gene amplification were determined by fluorescence in situ hybridization in cells from the same samples. We reasoned that if there is a specific order in which genetic changes occur, the same early changes would be found consistently in the cells with the fewest abnormalities. We reasoned further that late-developing abnormalities would not occur alone in individual cells but would almost always be found together with the early changes inherited by the same cells. By these criteria, abnormalities involving p53 generally occurred early in the course of development of invasive breast cancers, whereas ras protein overexpression was found to be a late-occurring phenomenon. Within individual tumors, cellular p53 overexpression was often observed alone in individual cells, whereas ras protein overexpression was rarely observed in the absence of p53 overexpression and/or Her-2/neu overexpression in the same cells. Furthermore, the intracellular level of each abnormally expressed protein was found to increase progressively as new abnormalities were acquired. Infiltrating ductal carcinomas exhibited characteristic phenotypic patterns in which p53 allelic loss and/or p53 protein overexpression, Her-2/neu amplification and/or overexpression, aneuploidy, and ras overexpression accumulated within individual cells. However, this pattern was not a prominent feature of lobular breast cancers. All six lobular breast cancers studied were diploid. p53 allelic loss and/or early p53 overexpression, and late ras cooverexpression in the same cells were less common in lobular breast cancers than in infiltrating ductal carcinomas. Although Her-21neu overexpression was a common finding in lobular breast cancers, Her-2/neu amplification was not observed in these tumors.

Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> HER-2/NEU --> ras sequence

INTRODUCTION

The sequence of genetic evolutionary abnormalities that have occurred in a given lung cancer tumor before tumor sampling can be inferred from patterns of intracellular co-occurrence of these abnormalities in tumor cell subpopulations at the time of sampling. The same evolutionary sequences that are present within each lung cancer were evident in intertumor comparisons.

METHODS

Correlated cell by cell measurements of cell DNA content, p53, Her-2/neu, and ras proteins were obtained by multiparameter flow cytometry on 46 surgically resected stage I-III primary non-small cell lung cancers. Early evolutionary changes were identified by the fact that they could appear alone in individual cells. Later appearing abnormalities were identified by the fact that they were accompanied by early abnormalities in the same cells. Patients were followed prospectively. Evolutionary patterns observed in individual tumors were correlated with subsequent clinical outcome of patients undergoing surgical resection.

RESULTS

Three common patterns were identified: (I) a diploid DNA pathway consisting of the sequence p53 overexpression --> Her-2/neu overexpression --> ras overexpression, (II) an aneuploid DNA pathway with the same p53 --> Her-2/neu --> ras sequence, and (III) a pathway in which none of the intracellular protein measurements made here were abnormal. Fourteen tumors recurred after 11.5 months' median study time. Nine of 12 recurrences in pathways I and II occurred in patients whose tumors were far advanced along these molecular genetic pathways.

CONCLUSIONS

Multiparameter cell-based genetic evolutionary studies may be a promising approach for identifying patients with stage I-III non-small cell lung cancer at high risk for recurrence.

The diagnostic value, parental and patient acceptability of micturating cysto-urethrography in children

OBJECTIVES

To evaluate the medical indications and outcome including psychological and physical consequences of micturating cysto urethrography.

METHODS

A prospective study of 165 consecutive children undergoing MCUG during a 3 month period. Medical data, including outcome was recorded. The distress of the child was recorded by the radiographer at the time of the examinations. Postal questionnaires were sent to parents one week after the test to obtain information on their own and their child's perception of the test, and any physical and/or behavioural changes.

RESULTS

Age distribution for first and subsequent MCUG. [table: see text] 73% of first MCUG's were requested because of urinary tract infection. 52% of first MCUG's in infants were abnormal compared with 13% in older children aged 1 to 4 years. 29 children aged 4 and over underwent a second or subsequent MCUG (53% abnormal). These children would be suitable for indirect cystography. One quarter of children experienced difficulty in passing urine following the test, haematuria was experienced by four. Radiographers recorded severe distress in 27% of children and 27% of parents also recorded distress.

CONCLUSIONS

A high incidence of distress was detected for both parent and child. Units should establish special guidelines for the use of this invasive procedure. A clear explanation of the investigation to parents and children should be standard practice. Routine employment of sedation for patients may be advisable. Alternative methods of imaging should be considered and evaluated, and indirect isotope cystography employed where appropriate.

Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning

Ciprofloxacin is effective for treating pulmonary infection in adult cystic fibrosis patients, and demonstrates excellent efficacy against Pseudomonas aeruginosa, but its use in paediatric cystic fibrosis patients has been limited because quinolone-induced cartilage toxicity has been observed in juvenile animals and has been considered a potential risk for children. Children with cystic fibrosis (n = 26; aged 6-16 years), with proven P. aeruginosa colonization of their sputum, were enrolled into a 14-day, open, non-comparative study. Patients were assigned to twice-daily treatment with oral ciprofloxacin 250 mg, 500 mg or 750 mg, depending on their body weight. None of the patients exhibited any signs or symptoms of arthropathy, as assessed by magnetic resonance imaging of the right knee, during or immediately after treatment, or at the 3-month post-therapy assessment. Cough, sputum production and sputum purulence were improved in more than 70% of patients. Patients showed a mean weight increase of 0.4 kg (95% confidence interval 0.1 to 0.7 kg) over the study period. Only one patient required a repeat chest radiograph, which showed no resolution of the abnormal radiographic appearances. Three patients reported adverse events during the trial, none of which were considered to be related to the study treatment.

Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients

Multiparameter flow cytometry studies were performed on cells from the primary tumors of 94 patients with breast cancer. Correlated cellular measurements of cell DNA content, Her-2/neu, epidermal growth factor receptor (EGFR), and p21ras levels were performed on each of 5,000 to 100,000 cells from each tumor. When criteria for positivity were matched with those in common use for immunohistochemical studies, 28 of 94 (30%) breast cancers were classified as positive for Her-2/neu overexpression. When similar criteria were applied to the EGFR measurements, 23 of 94 (24%) cases were classified as positive for EGFR overexpression. Similarly, 23 of 94 (24%) cases were classified as positive for p21ras overexpression. By conventional flow cytometric criteria for DNA ploidy, 24 cases were diploid, 28 were tetraploid, and 42 were aneuploid. When the measurements were treated as separate sets of data, the only statistically significant correlations noted were the high frequency of diploid tumors, which did not overexpress any of the three oncogenes studied (P < 0.05), and an association between Her-2/neu overexpression and aneuploidy (P < 0.03). When the data were treated as correlated intracellular measurements, 90 of the 94 tumors studied contained a population of cells in which the intracellular levels of Her-2/neu expression were directly correlated with the levels of EGFR expression in the same cells. The ratio of Her-2/neu molecules to EGFR molecules in the same cells exceeded 1 in the majority of tetraploid and aneuploid cases and was close to or less than 1 in the majority of diploid cases. In nearly all tumors, p21ras overexpression was observed only in cells that overexpressed Her-2/neu, EGFR, or both, and p21ras levels per cell were more closely correlated with levels of EGFR per cell in the same cells than with Her-2/neu levels per cell. The data are consistent with a model in which heterodimerization of Her-2/neu and EGFR in individual cells is achieved by one of several genetic evolutionary pathways, all of which commonly lead to p21ras overexpression. The two major genetic evolutionary pathways identified in this study are an aneuploid, Her-2/neu overexpression-driven pathway seen in 59 of 94 tumors, and a diploid, EGFR overexpression-driven pathway seen in 19 of 94 tumors. All tumors with Her-2/neu:EGFR ratios greater than 2 contained an infiltrating ductal carcinoma component, whereas all infiltrating pure lobular carcinomas had Her-2/ neu:EGFR ratios that were less than 2. All of the genetic evolutionary pathways identified in this study were represented among the 11 tumors from patients who experienced early tumor recurrences.

Three computational systems for disclosing medical data in the year 1999

Today most organizations release and receive medical data with all explicit identifiers, such as name, address, and phone number, removed in the incorrect belief that patient confidentiality is maintained because the resulting data look anonymous. We examine three computer programs that do maintain patient confidentiality when disclosing electronic medical records: the Scrub System which locates personally-identifying information in letters between doctors and notes written by clinicians; the Datafly System which generalizes data within the record based on a profile of the recipient at the time of access; and, the mu-Argus System which is becoming a European standard for disclosing public use data. The techniques presented in these systems help protect confidentiality in the face of a changing globally-networked society with immediate access to volumes of personal data.